|
1
|
Young IR, Clarke GJ, Bailes DR, Pennock
JM, Doyle FH and Bydder GM: Enhancement of relaxation rate with
paramagnetic contrast agents in NMR imaging. J Comput Tomogr.
5:543–547. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carr DH, Brown J, Bydder GM, Weinmann HJ,
Speck U, Thomas DJ and Young IR: Intravenous chelated gadolinium as
a contrast agent in NMR imaging of cerebral tumours. Lancet.
1:484–486. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tang JB, Sheng YQ, Hu HJ and Shen YQ:
Macromolecular MRI contrast agents: structures, properties and
applications. Prog Polym Sci. 38:462–502. 2013. View Article : Google Scholar
|
|
4
|
Geraldes CFGC and Laurent S:
Classification and basic properties of contrast agents for magnetic
resonance imaging. Contrast Media Mol Imaging. 4:1–23. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mitchell DG: Liver I: Currently available
gadolinium chelates. Magn Reson Imaging Clin N Am. 4:37–51.
1996.PubMed/NCBI
|
|
6
|
Wood ML and Hardy PA: Proton relaxation
enhancement. J Magn Reson Imaging. 3:149–156. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gandhi SN, Brown MA, Wong JG, Aguirre DA
and Sirlin CB: MR contrast agents for liver imaging: what, when,
how. Radiographics. 26:1621–1636. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shokrollahi H: Contrast agents for MRI.
Mater Sci Eng C. 33:4485–4497. 2013. View Article : Google Scholar
|
|
9
|
Yurt A and Kazanci N: Investigation of
magnetic properties of various complexes prepared as contrast
agents for MRI. J Mol Struct. 892:392–397. 2008. View Article : Google Scholar
|
|
10
|
Harisinghani MG, Jhaveri KS, Weissleder R,
Schima W, Saini S, Hahn PF and Mueller PR: MRI contrast agents for
evaluating focal hepatic lesions. Clin Radiol. 56:714–725. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhen ZP and Xie J: Development of
manganese-based nanoparticles as contrast probes for magnetic
resonance imaging. Theranostics. 2:45–54. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silva AC, Lee JH, Aoki L and Koretsky AR:
Manganese-enhanced magnetic resonance imaging (MEMRI):
methodological and practical considerations. NMR Biomed.
17:532–543. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin YJ and Koretsky AP: Manganese ion
enhances T-1-weighted MRI during brain activation: An approach to
direct imaging of brain function. Magn Reson Med. 38:378–388. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paratala BS, Jacobson BD, Kanakia S,
Francis LD and Sitharaman B: Physicochemical characterization, and
relaxometry studies of micro-graphite oxide, graphene
nanoplatelets, and nanoribbons. PloS One. 7:e381852012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nakamura H, Ito N, Kotake F, Mizokami Y
and Matsuoka T: Tumor-detecting capacity and clinical usefulness of
SPIO-MRI in patients with hepatocellular carcinoma. J
Gastroenterol. 35:849–855. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Na HB, Song IC and Hyeon T: Inorganic
nanoparticles for MRI contrast agents. Adv Mater. 21:2133–2148.
2009. View Article : Google Scholar
|
|
17
|
Taylor RM, Huber DL, Monson TC, Ali AMS,
Bisoffi M and Sillerud LO: Multifunctional iron platinum stealth
immunomicelles: targeted detection of human prostate cancer cells
using both fluorescence and magnetic resonance imaging. J Nanopart
Res. 13:4717–4729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Thunus L and Lejeune R: Overview of
transition metal and lanthanide complexes as diagnostic tools.
Coordin Chem Rev. 184:125–155. 1999. View Article : Google Scholar
|
|
19
|
Sijens PE, van den Bent MJ, Nowak PJ, van
Dijk P and Oudkerk M: 1H chemical shift imaging reveals loss of
brain tumor choline signal after administration of Gd-contrast.
Magn Reson Med. 37:222–225. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang CA: Magnetic resonance imaging
contrast agents. Design and physicochemical properties of
gadodiamide. Invest Radiol. 28(Suppl 1): S21–S27. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Runge VM, Clanton JA, Herzer WA, Gibbs SJ,
Price AC, Partain CL and James AE Jr: Intravascular contrast agents
suitable for magnetic resonance imaging. Radiology. 153:171–176.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Runge VM, Schoerner W, Niendorf HP,
Laniado M, Koehler D, Claussen C, Felix R and James AE Jr: Initial
clinical evaluation of gadolinium DTPA for contrast-enhanced
magnetic resonance imaging. Magn Reson Imaging. 3:27–35. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaplan GD, Aisen AM and Aravapalli SR:
Preliminary clinical trial of gadodiamide injection: a new nonionic
gadolinium contrast agent for MR imaging. J Magn Reson Imaging.
1:57–62. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Runge VM, Dean B, Lee C, Carolan F and
Heard G: Phase III clinical evaluation of Gd-HP-DO3A in head and
spine disease. J Magn Reson Imaging. 1:47–56. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cordova-Fraga T, Sosa M,
Hernandez-Gonzalez MA, Reyes-Aguilera JA, Solorio S, Ramirez C,
Bautista-Flores E, Reynaga G, Avila-Rodriguez M and De la
Roca-Chiapas JM: Medlar (Achras sapota L.) as oral contrast agent
for MRI of the gastrointestinal tract. Appl Magn Reson. 42:161–167.
2012. View Article : Google Scholar
|
|
26
|
Mayo-Smith WW: Computed body tomography
with MRI correlation. AJR Am J Roentgenol. 173:2661999.
|
|
27
|
Jacobs KE, Behera D, Rosenberg J, Gold G,
Moseley M, Yeomans D and Biswal S: Oral manganese as an MRI
contrast agent for the detection of nociceptive activity. NMR
Biomed. 25:563–569. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li KC, Tart RP, Fitzsimmons JR, Storm BL,
Mao J and Rolfes RJ: Barium sulfate suspension as a negative oral
MRI contrast agent: in vitro and human optimization studies. Magn
Reson Imaging. 9:141–150. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Verloh N, Utpatel K, Haimerl M, Zeman F,
Fellner C, Fichtner-Feigl S, Teufel A, Stroszczynski C, Evert M and
Wiggermann P: Liver fibrosis and Gd-EOB-DTPA-enhanced MRI: A
histopathologic correlation. Sci Rep. 5:154082015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Weissleder R, Bogdanov A and Papisov M:
Drug targeting in magnetic resonance imaging. Magn Reson Q.
8:55–63. 1992.PubMed/NCBI
|
|
31
|
Ahmad MW, Xu W, Kim SJ, Baeck JS, Chang Y,
Bae JE, Chae KS, Park JA, Kim TJ and Lee GH: Potential dual imaging
nanoparticle: Gd2O3 nanoparticle. Sci Rep. 5:85492015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Edelman RR, Siegel JB, Singer A, Dupuis K
and Longmaid HE: Dynamic MR imaging of the liver with Gd-DTPA:
initial clinical results. AJR Am J Roentgenol. 153:1213–1219. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Balci NC and Semelka RC: Contrast agents
for MR imaging of the liver. Radiol Clin North Am. 43:887–898.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nolte-Ernsting C, Adam G, Bücker A, Berges
S, Bjørnerud A and Günther RW: Abdominal MR angiography performed
using blood pool contrast agents: comparison of a new
superparamagnetic iron oxide nanoparticle and a linear gadolinium
polymer. AJR Am J Roentgenol. 171:107–113. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lauffer RB, Parmelee DJ, Dunham SU,
Ouellet HS, Dolan RP, Witte S, McMurry TJ and Walovitch RC: MS-325:
albumin-targeted contrast agent for MR angiography. Radiology.
207:529–538. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cavagna FM, Lorusso V, Anelli PL, Maggioni
F and de Haën C: Preclinical profile and clinical potential of
gadocoletic acid trisodium salt (B22956/1), a new intravascular
contrast medium for MRI. Acad Radiol. 9(Suppl 2): S491–S494. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Curtet C, Maton F, Havet T, Slinkin M,
Mishra A, Chatal JF and Muller RN: Polylysine-Gd-DTPAn and
polylysine-Gd-DOTAn coupled to anti-CEA F(ab′)2 fragments as
potential immunocontrast agents. Relaxometry, biodistribution, and
magnetic resonance imaging in nude mice grafted with human
colorectal carcinoma. Invest Radiol. 33:752–761. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Løkling KE, Fossheim SL, Skurtveit R,
Bjørnerud A and Klaveness J: pH-sensitive paramagnetic liposomes as
MRI contrast agents: in vitro feasibility studies. Magn Reson
Imaging. 19:731–738. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jung CW and Jacobs P: Physical and
chemical properties of superparamagnetic iron oxide MR contrast
agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging.
13:661–674. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Taupitz M, Schnorr J, Abramjuk C, Wagner
S, Pilgrimm H, Hünigen H and Hamm B: New generation of
monomer-stabilized very small superparamagnetic iron oxide
particles (VSOP) as contrast medium for MR angiography: preclinical
results in rats and rabbits. J Magn Reson Imaging. 12:905–911.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jung KH, Kim HK, Park JA, Nam KS, Lee GH,
Chang Y and Kim TJ: Gd Complexes of DO3A-(Biphenyl-2,2′-bisamides)
Conjugates as MRI Blood-Pool Contrast Agents. ACS Med Chem Lett.
3:1003–1007. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bourrinet P, Bengele HH, Bonnemain B,
Dencausse A, Idee JM, Jacobs PM and Lewis JM: Preclinical safety
and pharmacokinetic profile of ferumoxtran-10, an ultrasmall
superparamagnetic iron oxide magnetic resonance contrast agent.
Invest Radiol. 41:313–324. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Weinmann HJ, Ebert W, Misselwitz B and
Schmitt-Willich H: Tissue-specific MR contrast agents. Eur J
Radiol. 46:33–44. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Corot C and Warlin D: Superparamagnetic
iron oxide nanoparticles for MRI: contrast media pharmaceutical
company R&D perspective. Wiley Interdiscip Rev Nanomed
Nanobiotechnol. 5:411–422. 2013.PubMed/NCBI
|
|
45
|
Runge VM: A comparison of two MR
hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA. J
Comput Assist Tomogr. 22:643–650. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Torres CG, Lundby B, Sterud AT, McGill S,
Gordon PB and Bjerknes HS: MnDPDP for MR imaging of the liver -
Results from the European phase III studies. Acta Radiol.
38:631–637. 1997.PubMed/NCBI
|
